**PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT** **Prepared at the request of the Board of Directors of Asterix Robotics** **Re: Shareholder challenge to the NovaSense acquisition — liability assessment and recommended course of action** --- ## I. Executive summary 1. **Elena Voss will almost certainly be treated, at least at the pleading stage, as a controller for purposes of this transaction.** She lacks majority voting power (34%), but the combination of founder status, the CEO/chair roles, her nomination of six of nine directors, two management directors, her pre-committee negotiation of the term sheet, her public statement of commitment, and her explicit timing pressure on the committee supplies a strong "actual control over the challenged transaction" theory. 2. **The MFW-style safe harbor fails on at least four independent grounds**: the conditions were not imposed *ab initio*; the committee's independence is reasonably doubted; the committee's diligence is vulnerable as grossly negligent; and the shareholder vote was not fully informed. **Entire fairness applies, with the burden of persuasion on defendants**, because neither protective device was effective. 3. **Even if Elena is found not to be a controller, there is no cleansing.** The director approval was not by a fully informed, disinterested majority (Elena concealed the $8 million side payment from the board itself), and the shareholder vote was materially uninformed. So the standard of review is the same either way. This materially reduces the value of litigating the controller question. 4. **The concealed $8 million carried-interest payment is the single most dangerous fact in the case.** It is an undisclosed material personal benefit, it was withheld from the special committee and from shareholders, it created a threshold incentive tied to a $150 million price, and it is not exculpable. It converts what might have been an exculpated process case into a non-exculpable loyalty/bad-faith case against Elena and potentially into federal securities exposure for the company. 5. **A motion to dismiss will likely be denied as to Elena and largely granted or narrowed as to the non-committee outside directors.** Demand futility is likely excused. Discovery will be broad and intrusive, including Elena's personal devices and communications with the NovaSense lead investor, and Peak's internal fee and valuation files. 6. **Recommended course:** (a) form an independent litigation committee ("ILC") of the genuinely unconflicted outside directors, with its own counsel and financial expert, immediately; (b) do **not** present a unified defense with Elena — sever counsel and consider immediate governance separation; (c) affirmatively investigate and pursue the corporation's own claims against Elena, Peak, and the NovaSense lead investor; (d) preserve documents and assess whether corrective disclosure or self-reporting is required; (e) pursue a global mediated resolution once the ILC has a factual record, funded primarily by Elena, Peak, and insurance, coupled with governance relief; (f) adopt the prospective governance reforms in Part XIII, framed expressly as forward-looking best practice and not as an admission. --- ## II. Is Elena a controller? **Legal test (Rule 3):** >50% voting power, or actual control over the board or the challenged transaction. **She does not meet the numerical test.** 34% is meaningful but not majority. Standing alone, a 34% block does not create controller status. **The transaction-specific control theory is strong.** The relevant indicia: - **Structural influence:** Founder, CEO, and board chair — the same person who sets the agenda, controls the flow of information, and evaluates management directors' careers. Six of nine directors were her nominees. Two are her direct subordinates as officers. - **Process capture:** She negotiated the preliminary term sheet *before* any committee existed, thereby setting the price anchor. The committee's later "negotiation" occurred inside a frame she constructed. - **Public pre-commitment:** Describing the companies as "nearing a transformative combination" publicly signaled that the deal was the CEO's fixed objective and raised the reputational cost to the committee of saying no. - **Coercive framing:** Telling the committee that delay could let a competitor buy NovaSense — a competitive-loss narrative deployed by the interested party to compress the committee's deliberation and deter a market check — is a classic actual-control fact. - **Undisclosed self-interest:** Withholding the $8 million side payment deprived the board of the information needed to police her, which itself evidences functional dominance of the information environment. **Assessment:** A court will very likely sustain a well-pleaded allegation of transaction-specific control at the pleading stage; a reasonable probability (I would put it well above 50%) that control is found after trial. But note the strategic point in Part IV: because the alternative cleansing route (Rule 6) also fails, winning the controller fight does **not** deliver business-judgment review. We should therefore contest control to preserve burden and framing arguments, but should not invest heavily or make settlement decisions contingent on it. --- ## III. Do the committee and the vote change the standard of review? Under Rule 4, business-judgment review is available only if the transaction was conditioned **from the outset** on **both** an independent, fully empowered, duly careful committee **and** an informed, uncoerced majority-of-the-minority vote. Each element fails. ### A. Not conditioned *ab initio* The committee was formed **after** Elena personally negotiated a preliminary term sheet and after she publicly announced a near-agreement. The conditions therefore were not in place before substantive economic negotiation began. This alone defeats the safe harbor. The purpose of the *ab initio* requirement is to ensure the controller never gets to bargain against the fiduciaries with the leverage of a partially-made deal; here she did exactly that, and then publicly raised the switching cost of rejection. We may argue the term sheet was "preliminary" and non-binding, and that the announcement was aspirational. That argument is weak on these facts: the ultimate price ($190 million) never moved off the founder-negotiated frame, and the announcement was made *before* the committee existed. ### B. The committee is not demonstrably independent The charity director chairs an organization that receives approximately **$500,000 annually from Elena's family foundation, representing 8% of its budget.** Under Rule 9, this is far more than ordinary friendship. The director's own institutional position, prestige, and effectiveness depend on the continued flow of funds controlled by the interested party. Delaware courts have found reasonable doubt about independence on comparable charitable-dependency facts. Because the committee had only three members, the taint of one member is structurally fatal — a two-person effective committee, and the risk that the conflicted member influenced deliberations, deprives the committee of the character MFW requires. The other two members appear unconflicted on the facts given, but that requires confirmation in discovery (business relationships, prior board service with Elena, personal investments, family employment). ### C. The committee was not "fully empowered" in substance Formally it could "negotiate or reject." Substantively: - It inherited a price anchor and a public commitment. - It was told delay risked losing the asset — an artificial deadline imposed by the counterparty-in-interest. - It retained an adviser with a $12 million, five-year financial dependency on Elena, on the basis of a disclosure that concealed the magnitude of that dependency. A committee that cannot obtain honest advice is not empowered. - There is no indication it had authority to explore, or actually considered pursuing, the three alternative targets as substitutes, or to engage a second adviser. ### D. The committee's duty of care is not satisfied Independent grounds for a gross-negligence finding: 1. **The earlier, materially lower management forecast** was never surfaced in board materials. When two forecasts prepared two months apart diverge substantially, the divergence *is* the valuation question. The committee never interrogated why the seller's growth projections accelerated once a sale was in view. 2. **No sensitivity analysis on the 61% customer.** A single customer terminable on 90 days' notice generating nearly two-thirds of revenue is the dominant risk in the asset. Discussing "concentration generally" without quantifying downside is the equivalent of not analyzing it. The contract's presence in the data room does not discharge the committee's duty; it aggravates it, because the information was available and unused. 3. **No market check whatsoever**, in the face of a controller-driven urgency narrative and available alternatives. A committee is not required to run an auction, but it must have a principled basis for the price. Here the only price evidence was a conflicted adviser's range derived from seller-supplied projections. 4. **No apparent inquiry into the adviser's conflicts** beyond accepting "historical relationships." ### E. The shareholder vote was not fully informed The 54% approval by disinterested shares satisfies the *form* of the condition but not the substance. The proxy omitted four categories of information (analyzed in Part VI), at least three of which are plainly material. Under Rule 8, material omissions defeat cleansing. Fifty-four percent is also a thin margin — plaintiffs will argue persuasively that disclosure of an $8 million secret payment to the CEO would have flipped the outcome, and the narrow margin makes that inference plausible rather than speculative. ### F. Conclusion on standard of review **Entire fairness, with the burden on the defendants.** Rule 5 shifts the burden only where *one* protection is effective; here neither was. Under the non-controller path (Rule 6), the result is the same: neither the director nor the shareholder approval was fully informed, and the approving board majority was not disinterested. There is no realistic path to business-judgment review on this record. --- ## IV. Effect of the post-hoc committee and the public commitment Three distinct consequences, which should be separated in our analysis: 1. **Doctrinal:** It defeats the *ab initio* condition and therefore the safe harbor outright. 2. **Evidentiary:** It supplies the strongest single piece of circumstantial evidence of actual control, and it explains the price. Where the founder sets the number and then publicly stakes her credibility on completion, the committee's subsequent approval at that same number carries little probative weight on fairness. 3. **Practical (for us):** It caps the persuasive value of everything the committee did afterwards. We should not build the defense principally on "there was a special committee." We should build it on **fair price** (Part VII), on **exculpation** for the non-Elena directors (Part IX), and on **causation** (the customer's post-closing termination). --- ## V. Committee independence, authority, diligence, good faith — summary grid | Element | Assessment | Key facts | |---|---|---| | Independence | **Fails / reasonable doubt** | Charity chair; $500k = 8% of budget from Elena's foundation; 1 of 3 members | | Authority (formal) | Adequate | Power to negotiate or reject | | Authority (functional) | **Fails** | Pre-set price anchor; public commitment; artificial deadline; conflicted adviser; no second opinion; no alternative-target mandate | | Care / diligence | **Fails (gross negligence plausible)** | Ignored earlier forecast; no customer sensitivity analysis; no market check; no adviser-fee inquiry | | Good faith | Probably **satisfied** (no conscious disregard shown) | Committee met, negotiated, engaged an adviser, discussed concentration; no evidence it knew of the side payment | The good-faith finding matters enormously: it is the difference between exculpated care claims and non-exculpable loyalty claims for the two unconflicted committee members. Our defense should protect that distinction aggressively. Conversely, the charity director's exposure is different in kind, because a lack-of-independence finding is a loyalty finding. --- ## VI. Materiality of the omissions Standard (Rule 8): would a reasonable shareholder consider it important in deciding how to vote? **1. The $8 million side payment — unquestionably material.** It is a personal benefit not shared with shareholders, it more than doubles her economic interest in a sale, and it is *structured around a $150 million threshold*, giving her a strong interest in any deal above that figure and essentially no interest in price discipline above it. It also constitutes concealment from the fiduciaries charged with policing her. This omission alone defeats both the director and the shareholder cleansing routes and independently supports bad faith and improper personal benefit. **2. Peak's $12 million in prior fees — material.** "Historical relationships" is a euphemism that conveys nothing about magnitude. Shareholders assessing the reliability of the only fairness opinion in the record would want to know that the adviser had earned $12 million from the interested party over five years. Delaware authority on banker conflict disclosure is firmly on plaintiffs' side here. **3. The earlier, lower management forecast — material.** Projections are the principal input to any valuation. A forecast prepared two months before discussions showing substantially slower growth, superseded by a seller-prepared "rapid growth" case once a sale was in view, is precisely the kind of information a reasonable shareholder wants. **Placement in the data room is not disclosure to shareholders**; there is no constructive-disclosure doctrine for proxy purposes. (Data-room availability *is* relevant to the committee's care — it makes the omission from board materials worse, not better.) **4. The customer termination right — material.** With 61% revenue concentration and a 90-day out, the termination right is the central risk. The subsequent termination and 70% write-down do not establish materiality retrospectively, but they powerfully corroborate it. **Conclusion:** All four omissions are material; at minimum the first three are indefensible. The vote does not cleanse. In addition, these omissions create a **federal proxy exposure** (negligence-based misstatement/omission claim) and, depending on scienter, a potential Rule 10b-5 claim against Elena and possibly the company arising from the proxy and any subsequent statements. That exposure should be assessed separately and immediately, along with related-person-transaction disclosure obligations for the side payment. --- ## VII. Entire fairness: fair dealing and fair price ### A. Fair dealing — defendants lose this prong Initiation by the interested party; pre-committee negotiation of price; public pre-commitment; committee formed late and populated in part by a financially dependent member; conflicted adviser retained on an incomplete conflict disclosure; seller-supplied projections accepted without reconciliation to the company's own earlier forecast; no sensitivity analysis on the dominant risk; no market check; timing pressure applied by the interested party; concealment of the interested party's largest economic incentive. There is no realistic argument that fair dealing was satisfied. ### B. Fair price — this is our real defense Points in our favor: - **$190 million sits inside Peak's $175–210 million range**, modestly above the midpoint but not at the top. - Fairness is measured **at signing**, on information then reasonably available. The subsequent customer loss nine months later is an intervening event, and the 70% write-down is an accounting measure reflecting post-closing developments, not a determination that the company overpaid by 70% *ex ante*. - Plaintiffs must prove damages, and the loss-causation argument (exogenous customer decision) is genuinely contestable. Points against us: - Peak's range is derived from the **inflated seller projections** and prepared by an adviser with a $12 million dependency. A court may discount or disregard it entirely. - Reconstructing value on the **earlier, slower-growth forecast** will produce a materially lower number. Plaintiffs' expert will do exactly that. - The 90-day termination right on 61% of revenue should have been priced — via a lower multiple, an escrow, an earnout, a contingent price adjustment, or a risk-adjusted DCF. **Nothing in the record suggests any risk allocation for this exposure.** That is the strongest damages theory: not that the customer left, but that the *risk* the customer could leave on 90 days' notice was never paid for. - Because process was unfair and the burden rests on defendants, the court will resolve valuation ambiguities against us. **Realistic assessment:** a court is likely to find the transaction not entirely fair. Quantum is genuinely uncertain. Plaintiffs will anchor on the full write-down (roughly $133 million); we will argue overpayment, if any, is a fraction of that. A litigated damages outcome in the $20–70 million range strikes me as the central expectation, with meaningful tail risk in both directions. --- ## VIII. Potential liability by defendant ### A. Elena Voss — severe, non-exculpable exposure - **Duty of loyalty:** stood on both sides; received a material benefit not shared with shareholders (22% NovaSense equity plus the $8 million carry). - **Bad faith and improper personal benefit:** concealment of the side payment from the committee and from shareholders. This is not a care failure; it is deception of the fiduciaries she was obliged to inform. Exculpation is unavailable (Rule 10). Indemnification and advancement will likely be unavailable at the end of the day (no good-faith basis), and D&O coverage may be barred by fraud/personal-profit exclusions once a final adjudication or admission exists. - **Also as officer:** duty of care claims against her as CEO are not eliminated by a charter provision protecting directors, and officer exculpation (where available at all) does not extend to derivative claims. - **Remedies against her specifically:** disgorgement of the $8 million; her share of any damages award; potential clawback of incentive compensation; potential rescission of benefits; fee exposure. ### B. The charity-chair committee member — moderate to serious If the court finds independence compromised, the claim is characterized as loyalty, not care, and **exculpation does not apply**. Defenses: the tie is to a third-party charity, not to her personally; she received no personal financial benefit; she did not know of the side payment; her vote was one of three and the price was within a fairness range. Realistically, she survives dismissal and settles within insurance. ### C. The other two committee members — likely exculpated Their exposure is grounded in care (inadequate diligence, no market check, no sensitivity analysis, reliance on a conflicted adviser). Absent evidence they knew of the side payment or Peak's fee history and concealed it, exculpation should defeat monetary liability. They remain necessary witnesses and remain exposed to non-monetary relief and to the burden of discovery. Watch for a bad-faith theory built on **conscious disregard** — i.e., that they knew the data room contained the earlier forecast and the termination right and deliberately kept them out of board materials and the proxy. If discovery shows that, exculpation is at risk. ### D. The two executive directors and other Elena nominees Interested/non-independent for demand-futility purposes, but liability requires more. Their exposure is: approving the transaction on an uninformed basis and approving a proxy they knew or should have known was incomplete. Mostly care-based, therefore exculpated as directors — **but the two executives are also officers**, and officer conduct is not covered by a director exculpation clause. If either participated in preparing the projections, the proxy, or the board materials, or knew of the side payment, their exposure escalates sharply. This must be a priority discovery topic for the ILC. ### E. Peak Partners — a genuine and valuable target **Aiding and abetting (Rule 11)** requires a fiduciary breach (present), knowing participation, and damages. Supporting facts: - Peak knew the actual magnitude of its own fees and drafted or approved a disclosure describing them merely as "historical relationships." Concealing one's own conflict from the committee one is advising is the paradigm of knowing participation. - Peak knew or should have known of the earlier lower forecast (it was in the data room it was engaged to review) and delivered a fairness range built on the more optimistic seller case without reconciliation. - Peak did not deliver a sensitivity analysis on a 61%-concentration, 90-day-terminable contract — an omission so basic that a court may infer it was conflict-driven rather than negligent. **Additionally, Asterix holds its own direct claims** against Peak: breach of the engagement agreement, professional negligence, breach of the duty of candor to its committee-client, and contractual indemnity. These are corporate assets. Pursuing them serves three functions: recovery, allocation of fault away from the directors, and demonstrating to the court and to shareholders that the board is acting adversely to the wrongdoers. ### F. The NovaSense lead investor The party who agreed to pay Elena $8 million contingent on a >$150 million sale participated in the corruption of Asterix's process. Consider claims for aiding and abetting, fraud, and civil conspiracy, and review the merger agreement for representations regarding projections, undisclosed arrangements with Asterix personnel, indemnity, and escrow. **This may be the least politically costly and most economically attractive recovery avenue.** It should be evaluated in the first 30 days. --- ## IX. Effect of the exculpation provision - It **eliminates monetary liability of directors for duty-of-care violations** — which covers most of what the outside directors and the two unconflicted committee members did wrong (diligence failures, no market check, no sensitivity analysis, negligent proxy review). - It **does not reach**: (i) Elena's loyalty breach, bad faith, and improper personal benefit; (ii) a lack-of-independence/loyalty finding against the charity director; (iii) any director shown to have acted in bad faith or with conscious disregard; (iv) **officer** liability, including Elena as CEO and the two executive directors in their officer capacities. - It does **not** bar equitable relief (rescission, rescissory relief, disgorgement, governance orders), does not bar fee shifting, and does not prevent plaintiffs from using care failures evidentially to prove unfairness and damages against the non-exculpated defendants. - Practical consequence: the case is really **Elena + Peak + (possibly) the charity director + officer-capacity claims**, with the remaining directors as defendants whose principal cost is discovery burden and insurance erosion. Our settlement architecture should reflect that allocation. --- ## X. Motion to dismiss and probable discovery ### A. Characterization The overpayment claim is **derivative** (harm to Asterix from paying too much for an asset). Demand futility applies. Disclosure claims tied to the vote may be pleaded as direct, but their principal function here is anti-cleansing rather than independent damages. Expect a parallel or consolidated **federal proxy/securities action** following the write-down. ### B. Demand futility Plaintiffs must show that at least five of nine directors are incapable of impartially considering a demand. Their count: Elena (received a material benefit; faces a substantial likelihood of non-exculpated liability); the two executive directors (employment-dependent on Elena, and facing officer-capacity exposure); the charity-chair committee member (independence doubt plus non-exculpated liability risk); and at least one more from among Elena's remaining nominees or the other committee members (substantial likelihood of liability if bad faith is adequately pleaded; or independence doubts developed through Section 220 books-and-records material). **Demand futility is likely to be excused.** ### C. Likely rulings - **Standard of review:** entire fairness. We lose this. - **Elena:** motion denied. Certain. - **Peak:** motion likely denied given the self-conflict-concealment allegations, though this is the closest call among the principal defendants; knowing participation is often a dismissal chokepoint. - **Charity director:** likely denied. - **Other two committee members:** could go either way; denial is likely if plaintiffs plead conscious disregard of the data-room documents with specificity. - **Non-committee outside directors:** dismissal reasonably likely on exculpation. - **Waste:** likely dismissed — $190 million within a $175–210 million professional range is not "no consideration a reasonable person would accept." ### D. Scope of discovery (expect it to be broad and painful) - Board and committee minutes, drafts, and all board/committee materials; committee members' notes; retention documents and engagement letters. - **Elena's personal communications and devices** — texts, personal email, messaging apps — with the NovaSense lead investor, her investment vehicle, Peak bankers, and individual directors. This is where cases of this type are won and lost. - The complete **side-agreement file**: the carried-interest instrument, its negotiation history, who at Asterix or its advisers knew, and when. - **Peak's internal files**: valuation models and iterations, internal fee/relationship databases, conflict-clearance memoranda, internal emails about the earlier forecast and the customer concentration, deal-team compensation. - **Data room access logs** — who opened the earlier forecast and the customer contract, and when. Expect plaintiffs to obtain these and to use them to convert care claims into bad-faith claims. - Proxy drafting files, comment sets, and communications with disclosure counsel regarding what to say about Peak's relationship and Elena's interests. - NovaSense's forecast preparation files and communications about why growth assumptions changed. - Third-party discovery of the terminated customer regarding the timing and reasons for termination and any pre-closing signals — **critical to both fair price and causation**. - Privilege fights, including a likely Garner-style challenge to privilege over committee/board advice. --- ## XI. Remedies and settlement exposure **Available remedies (Rule 12):** - **Damages** — overpayment measured as the difference between $190 million and fair value at signing. Plaintiffs anchor near the $133 million write-down; a court is more likely to find a risk-adjusted overpayment. - **Rescission** — impractical. NovaSense has been held nine months, has lost its principal customer, and has presumably been integrated. Unwinding is not feasible. - **Rescissory damages** — available in principle where rescission is impracticable and the fiduciary's conduct was egregious; the concealed side payment gives plaintiffs a credible request. This is the tail risk that most concerns me, because it can approach the full purchase price. - **Disgorgement** — the $8 million carry is essentially certain to be surrendered; treat it as the floor. - **Fee shifting** — plausible given the concealment; assume a substantial fee award or negotiated fee in any settlement. - **Governance relief** — near-certain component of any settlement; we should prefer to design it ourselves (Part XIII) rather than have it imposed. **Settlement exposure estimate (preliminary):** | Component | Range | |---|---| | Elena — disgorgement of carry | $8M (floor) | | Elena — additional personal contribution / comp clawback | $10–35M | | Peak — contribution / fee rebate / A&A settlement | $10–30M | | D&O insurance (Side A/B) for directors | Policy-limit dependent; assume meaningful erosion | | NovaSense lead investor / seller-side recovery (offset) | Potentially significant; assess early | | Plaintiffs' fees | $8–25M | | **Aggregate realistic band** | **$35–90M, with tail risk substantially higher if rescissory damages are seriously entertained** | Two structural points. First, **the company's net exposure can be reduced substantially by recoveries from Elena, Peak, and the seller side**; a derivative settlement in which the corporation is a net recipient rather than a net payer is achievable here and is the outcome we should target. Second, **insurance conflicts are acute**: Elena's conduct triggers fraud and personal-profit exclusions and creates allocation disputes with the other insureds. Notice must be given immediately, and coverage counsel retained separately. --- ## XII. Recommended course of action **1. Form an independent litigation committee now.** Composition: the two committee members without ties plus the remaining unconflicted outside directors. Exclude Elena, both executive directors, and the charity-chair director. Give it: authority to investigate; authority to retain independent legal counsel and an independent valuation expert; authority to decide whether to pursue, settle, or seek dismissal of claims on the corporation's behalf; authority to consider and act on claims against Elena, Peak, and the seller side; and access to all documents and personnel. Document the delegation with care — if we later seek to control the litigation, the ILC's independence and thoroughness will be scrutinized. **2. Do not mount a joint defense with Elena.** The corporation's interests and Elena's are directly adverse on the side payment. Separate counsel for Elena, for the outside directors, and for the company. Any joint-defense arrangement that includes Elena will be used to argue the board is captured and will contaminate the ILC. **3. Immediate governance separation of roles.** Elena should be recused from all matters relating to this litigation, the NovaSense integration, and any related-party matters. Appoint an independent board chair or, at minimum, a lead independent director with agenda control. Whether more is warranted — leave of absence, compensation clawback, or termination — is a judgment for the ILC after it assesses the concealment. Frame all of this as governance hygiene, not as an adjudication of wrongdoing. **4. Investigate and pursue the corporation's claims.** Priorities: (i) the side agreement — who knew, when, and whether anyone at Asterix or its advisers facilitated it; (ii) Peak — its conflict-clearance file and the drafting history of its disclosure; (iii) the seller and lead investor — merger-agreement representations, indemnity, escrow, and fraud claims. Pursuing Peak and the seller side is the highest-value, lowest-cost strategic move available: it recovers money, reallocates fault away from the directors, and establishes the board's bona fides. **5. Do not seek early settlement before the ILC has a record.** Settling now would (a) be priced off plaintiffs' anchor rather than ours, (b) forfeit our leverage against Peak and the seller, and (c) risk objections that the settlement was negotiated by a conflicted board. Target mediation after core document discovery and the ILC's valuation work — roughly six to nine months — when we can credibly test plaintiffs' damages case and offset it with third-party recoveries. **6. Defend selectively, not uniformly.** Concede nothing, but allocate resources to the three defenses that can actually move the outcome: **fair price** (the transaction was within a defensible range on information then available), **causation** (the customer's later termination was an independent business event), and **exculpation** (most directors cannot be held monetarily liable). Do not expend credibility defending the process or the *ab initio* question. **7. Address disclosure and regulatory obligations promptly.** With counsel, assess whether the side payment requires corrective or supplemental disclosure, related-person-transaction disclosure, an audit committee inquiry into whether management withheld information from auditors or the board, and whether voluntary self-reporting is advisable. Ensure a comprehensive litigation hold is in place immediately, including personal devices — a preservation failure would be far more damaging than any fact currently in the record. --- ## XIII. Governance changes (prospective; not an admission) Adopt these as a forward-looking related-party-transaction framework, memorialized as an improvement to existing practice: **Conflict transaction protocol** 1. Any transaction in which a director, officer, or holder of 10%+ has any economic interest must be **conditioned at the outset**, before any substantive economic discussion, on (a) approval by an independent committee and (b) a majority-of-the-minority vote. 2. **The interested party may not negotiate, may not communicate with the counterparty about terms, and may not make any public statement about the transaction** except as authorized by the committee. Written recusal protocol with an enforcement mechanism. 3. The committee's charter must expressly include the power to **say no definitively**, to explore and pursue alternatives, to set its own timetable, and to hire its own counsel and financial adviser. **Independence and disclosure** 4. Annual and transaction-specific independence questionnaires that expressly cover **charitable and philanthropic relationships**, family-office and foundation ties, carried-interest and profit-participation arrangements, co-investments, and side letters — with a bright-line disqualification where an interested party's contributions exceed a defined percentage of an affiliated organization's budget. 5. A standing policy requiring **affirmative written disclosure of every economic interest**, including contingent, deferred, and third-party payments, in any transaction the company considers. Certification requirement for the CEO and each director. **Adviser standards** 6. Committee advisers must deliver a **written conflicts disclosure quantifying all fees** received from any interested party and affiliates over a five-year lookback, before engagement, with the committee's retention decision documented. 7. Presumption in favor of an adviser with no material prior relationship with the interested party; where that is impracticable, a **second, independent fairness opinion** is mandatory. **Diligence standards** 8. Mandatory **reconciliation of any seller-supplied projections against the target's own most recent pre-transaction forecast**, with written explanation of material variances presented to the committee. 9. Mandatory **customer/supplier concentration analysis with quantified downside sensitivities** whenever any counterparty exceeds a defined revenue threshold, plus consideration of contractual risk allocation (escrow, earnout, contingent consideration, holdback). 10. A rule that **key documents must be escalated into committee materials**, not merely made available in a data room, with a diligence checklist certified by counsel and the adviser. 11. Committees should conduct a documented market check or record a specific, reasoned basis for declining one; **urgency asserted by an interested party is never a sufficient basis.** **Structural** 12. Separate the chair and CEO roles, or appoint a lead independent director with agenda and executive-session control. 13. Establish a board-level disclosure committee to review proxy and merger disclosure against the board's actual information base, with counsel's sign-off on conflict and projection disclosure. 14. Adopt a compensation clawback covering benefits obtained through undisclosed conflicts. 15. Review D&O coverage limits, Side A protection, and allocation provisions in light of this matter. --- ## XIV. Bottom line Entire fairness will apply and fair dealing cannot be defended. The board's realistic objectives are therefore: (1) protect the exculpated directors and preserve the good-faith finding for the unconflicted committee members; (2) shift the economic burden onto Elena, Peak, and the seller side, where it belongs; (3) contain damages through the fair-price and causation defenses; and (4) demonstrate to the court, shareholders, and the market that the independent directors — not the founder — now control the corporation's response. Every step recommended above serves those four objectives simultaneously.